Coronaviruses are a diverse group of viruses that include Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV). We have developed a hamster and ferret models for SARS-CoV-2 and an alpaca model for MERS-CoV. These models allow different vaccine and therapeutic strategies to be assessed for protection. If you are highly motivated and have a strong interest in the field of emerging viruses join our team as a post-doctoral fellow. We are looking for someone with significant experience in viral pathogenesis, animal models, and immunology. The successful candidate will be working towards understanding correlates of protection from various vaccines against SARS-CoV-2 and MERS-CoV. Furthermore, they will evaluate the vaccine potential in both in-vivo and in-vitro model systems. They will work with a team of researchers and support staff. Previous experience working in containment level 3 would be an assest but is not required.
Location: University of Saskatchewan Campus, Saskatoon, Saskatchewan, Canada
Principle Investigator: Dr. Darryl Falzarano, Viral Vaccine Development Program, VIDO
Financial Support: This project is funded by CIHR for a 2 year term. Salary will follow the university standard for a post-doctoral researcher and will be commensurate with experience.
Conditions: The successful candidate will be required to undergo and clear a reliability status screening assessment, background check, and criminal record check as a condition of employment. Candidates must be fluent in written and oral English communication.
How to Apply: Interested candidates are asked to submit their application in one single application document (pdf file) 1) statement of research interest, 2) a complete curriculum vitae (CV), and 3) contact information for three references online via the following link: https://vido-intervac.humi.ca/job-board/research/6433
Review of applications will begin immediately; however, applications will be accepted and evaluated until the position is filled. Only candidates selected for interview will be contacted.
Note: The University believes equity, diversity, and inclusion strengthen the community and enhance excellence, innovation and creativity. We are dedicated to recruiting individuals who will enrich our work and learning environments. All qualified candidates are encouraged to apply; however, in accordance with Canadian immigration requirements, Canadian citizens and permanent residents will be given priority. We are committed to providing accommodations to those with a disability or medical necessity. If you require an accommodation in order to participate in the recruitment process, please notify us and we will work together on the accommodation request. The University of Saskatchewan’s main campus is situated on Treaty 6 Territory and the Homeland of the Métis. We pay our respects to the First Nations and Métis ancestors of this place and reaffirm our relationship with one another. Together, we are uplifting Indigenization to a place of prominence at the University of Saskatchewan.
Qualifications: The successful candidate will have recently completed a PhD (in the past three years) in Microbiology, Biochemistry, Immunology, or another related discipline. The ideal candidate should have a strong background in virology, immunology, and/or vaccinology. Must be a team player with excellent oral and written communication skills. Effective organizational, and time management skills are required. Experience working with large animals would be an asset.
Please apply online
The Vaccine and Infectious Disease Organization (VIDO), a part of the University of Saskatchewan, is one of Canada’s largest research organizations focusing on vaccine research for both human and animal diseases. VIDO was the first organization in Canada to isolate SARS-CoV-2 and to develop an animal model of disease. It is also the first university organization in Canada to have a COVID-19 vaccine in clinical trials. The organization has the world’s largest and most advanced containment research facilities (CL3-Ag) with a large animal capacity. VIDO will be home to the Centre for Pandemic Research as well as a state-of-the-art level GMP vaccine manufacturing facility, which is currently under construction.